Plain-English translation of NCT04838301 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a medication called to see if it can help restore brain structure and improve thinking and memory in people with mild Alzheimer's disease. Researchers believe this medication may work by protecting and regenerating brain cells that are damaged by Alzheimer's. The study will compare the medication to a placebo (a dummy treatment) to see which group shows better brain health and cognitive improvement.
Alzheimer's disease currently has few treatments that can slow or reverse brain damage. This trial is exploring whether this medication might be able to regenerate and protect brain tissue, offering a new approach to help people in the early stages of the disease preserve their memory and thinking skills.
If you join this trial, you'll come to a clinic once per week for 6 months to receive a 30-minute IV infusion — either the new medication or a placebo (matching saline solution). You'll have brain imaging scans at the beginning, at 3 months, and at 6 months to track changes. If you're in the placebo group, you'll have the option to receive the actual medication for an additional 3 months after the initial 6-month period.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
United States